DUBLIN–(BUSINESS WIRE)–The “Market Spotlight: NHL: Peripheral T-cell lymphoma (PTCL)” report has been added to ResearchAndMarkets.com’s offering.
This Market Spotlight report covers the Peripheral T-Cell Lymphoma (PTCL) market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, recent events and analyst opinion, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- The publisher estimates that in 2017, there were approximately 19,950 incident cases of peripheral T-cell lymphoma (PTCL) worldwide, and forecasts that number to increase to 23,880 incident cases by 2026.
- It is estimated that the majority of diagnosed cases were in males in 2017.
- The incidence of PTCL is highest among older individuals aged 60+ years. The approved drugs in the PTCL space focus on a wide variety of targets. These drugs are administered via the intravenous and oral routes.
- The majority of industry-sponsored drugs in active clinical development for PTCL are in Phase II. Therapies in development for PTCL focus on a wide variety of targets. These therapies are administered via the oral and intravenous routes.
- High-impact upcoming events for drugs in the PTCL space comprise topline Phase II trial results for IPH4102 and an expected supplemental CHMP opinion for Adcetris.
- The overall likelihood of approval of a Phase I hematologic asset is 8.6%, and the average probability a drug advances from Phase III is 59.1%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.6 years in the overall oncology space.
- The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for PTCL have been in the early and mid-phases of development, with 93% of trials in Phase I-II, and only 7% in Phase III-IV.
- The US has a substantial lead in the number of PTCL clinical trials globally. France and the UK lead the major European markets, while China has the top spot in Asia.
- Clinical trial activity in the PTCL space is dominated by completed trials. Bristol Myers Squibb has the highest number of completed clinical trials for PTCL, with 11 trials.
- Bristol Myers Squibb leads industry sponsors with the highest overall number of clinical trials for PTCL, followed by Seagen and Takeda.
Key Topics Covered:
OVERVIEW
KEY TAKEAWAYS
DISEASE BACKGROUND
- Subtypes
TREATMENT
EPIDEMIOLOGY
MARKETED DRUGS
PIPELINE DRUGS
RECENT EVENTS AND ANALYST OPINION
- ALXN2075 for PTCL (December 8, 2019)
- Tipifarnib (Oncology) for PTCL (December 8, 2019)
- Copiktra for PTCL (December 7, 2019)
KEY UPCOMING EVENTS
PROBABILITY OF SUCCESS
LICENSING AND ASSET ACQUISITION DEALS
- Curon Picks Up China-Plus Rights to Rhizen’s Tenalisib
REVENUE OPPORTUNITY
CLINICAL TRIAL LANDSCAPE
- Sponsors by status
- Sponsors by phase
BIBLIOGRAPHY
APPENDIX
For more information about this report visit https://www.researchandmarkets.com/r/rozir
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900